EUVIMEDEUVIMED entdecken
EditorialOpen Access · CC BY 4.0

Small cell lung cancer (SCLC): At the door of targeted therapies

Krešimir Tomić, Semir Vranić

Biomolecules and Biomedicine · 29.08.2025 · 26 (1) · 1-4

DOI: 10.17305/bb.2025.13195 ↗

Kurz gefasst

Editorial in der Zeitschrift Biomolecules and Biomedicine, online erschienen am 29.08.2025. Verfasst von Krešimir Tomić und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, University Hospital Center Mostar, Mostar, Bosnia and Herzegovina. Hauptthemen laut MEDLINE: Small Cell Lung Carcinoma, Lung Neoplasms, Molecular Targeted Therapy. Die Arbeit wurde bisher 3-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Small-cell lung cancer (SCLC) is a tobacco-associated neuroendocrine tumor comprising ~15% of lung cancers (~150,000 cases/year). For decades, outcomes stagnated: most patients present with extensive-stage disease, screening rarely detects early tumors, surgery is seldom feasible, and platinum–etoposide remained the first-line standard with median overall survival (OS) 80% of SCLC, enables T-cell–redirecting therapy: the bispecific T-cell engager (BiTE®) tarlatamab improved OS to 13.6 vs 8.3 months over standard second-line chemotherapy, with manageable cytokine release syndrome and occasional ICANS. B7 homolog 3 (B7-H3, CD276), uniformly expressed across SCLC subtypes and linked to poor prognosis, is another compelling target: the antibody–drug conjugate ifinatamab deruxtecan achieved a 54.8% response rate and meaningful survival in heavily pretreated patients, earning FDA Breakthrough designation. Together, DLL3- and B7-H3–directed therapies (with additional ADCs against Trop-2 and SEZ6 in development) are redefining second-line and later care. Key next steps include optimizing sequencing/combination strategies, managing BiTE® specific toxicities, and developing predictive biomarkers. After decades of futility, SCLC is transitioning from uniform chemotherapy to a precision-medicine paradigm with cautious optimism.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Small Cell Lung CarcinomaLung NeoplasmsMolecular Targeted TherapyHumansImmune Checkpoint Inhibitors

Substanzen

Immune Checkpoint Inhibitors

Autor:innen und Institutionen

  • Department of Oncology, University Hospital Center Mostar, Mostar, Bosnia and Herzegovina.
  • College of Medicine, QU Health, Qatar University, Doha, Qatar.

Zitieren

APA

Tomić, K., & Vranić, S. (2025). Small cell lung cancer (SCLC): At the door of targeted therapies. Biomolecules and Biomedicine, 26(1), 1-4. https://doi.org/10.17305/bb.2025.13195

Vancouver

Tomić K, Vranić S. Small cell lung cancer (SCLC): At the door of targeted therapies. Biomolecules and Biomedicine. 2025;26(1):1-4. doi:10.17305/bb.2025.13195

BibTeX
@article{Tomi2025,
  author = {Tomić, Krešimir and Vranić, Semir},
  title = {Small cell lung cancer (SCLC): At the door of targeted therapies},
  journal = {Biomolecules and Biomedicine},
  year = {2025},
  volume = {26},
  number = {1},
  pages = {1--4},
  doi = {10.17305/bb.2025.13195}
}
Kostenlos starten →